The members of our Executive Board are dedicated to conducting research and publishing practice-changing guidance. We’re proud to share this list of their recent publications, all of which strongly support NATF’s mission to educate healthcare providers and patients about thrombosis and its complications.

Samuel Z. Goldhaber, MD – NATF President
  1. Association of ABO Blood Group Type with Cardiovascular Events in COVID-19. Nauffal V, Achanta A, Goldhaber SZ, Piazza G. J Thromb Thrombolysis. 2021 Jan 15. doi: 10.1007/s11239-020-02364-5. Online ahead of print. PMID: 33452583
  1. Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants. Collins P, Lewin A, Irving NV, Sylvester K, Fanikos J, Goldhaber SZ, Connors JM. Crit Pathw Cardiol. 2020 Dec 16;Publish Ahead of Print. doi: 10.1097/HPC.0000000000000251. Online ahead of print. PMID: 33337730
  1. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. O’Connell C, Escalante CP, Goldhaber SZ, McBane R, Connors JM, Raskob GE. Oncologist. 2021 Jan;26(1):e8-e16. doi: 10.1002/onco.13584. Epub 2020 Dec 4. PMID: 33275319
  1. Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. Lewin AR, Collins PE, Sylvester KW, Rimsans J, Fanikos J, Goldhaber SZ, Connors JM. Crit Pathw Cardiol. 2020 Dec;19(4):178-186. doi: 10.1097/HPC.0000000000000221. PMID: 33186279
  1. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB, Morrison RB, Leiva O, Fanikos J, Nauffal V, Almarzooq Z, Goldhaber SZ. J Am Coll Cardiol. 2020 Nov 3;76(18):2060-2072. doi:10.1016/j.jacc.2020.08.070. PMID: 33121712
  1. Assessment of Outcomes Among Patients with Venous Thromboembolism With and Without Chronic Kidney Disease. Goto S, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Weitz JI, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat A, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE Investigators. JAMA Netw Open. 2020 Oct 1;3(10):e2022886. doi: 10.1001/jamanetworkopen.2020.22886. PMID: 33112399
  1. Sulodexide Versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, Francese DP, Gibson CM, Piazza G, Goldhaber SZ, Eikelboom JW, Krumholz HM, Stone GW. Semin Thromb Hemost. 2020 Nov;46(8):908-918. doi: 10.1055/s-0040-1716874. Epub 2020 Oct 21. PMID: 33086402
  1. Reasons for New Patient Warfarin Referrals to an Anticoagulant Management Service in 2019: A Single Institution Experience. Sylvester KW, Wagner C, Lewin A, Fanikos J, Goldhaber SZ, Connors JM. J Thromb Thrombolysis. 2020 Oct 21. doi: 10.1007/s11239-020-02293-3. Online ahead of print. PMID: 33085044
  1. Age-Sex Specific Pulmonary Embolism-Related Mortality in the USA and Canada, 2000-18: An Analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death Database. Barco S, Valerio L, Ageno W, Cohen AT, Goldhaber SZ, Hunt BJ, Iorio A, Jimenez D, Klok FA, Kucher N, Mahmoudpour SH, Middeldorp S, Münzel T, Tagalakis V, Wendelboe AM, Konstantinides SV. Lancet Respir Med. 2021 Jan;9(1):33-42. doi: 10.1016/S2213-2600(20)30417-3. Epub 2020 Oct 12. PMID: 33058771
  1. Patients with Perceived High-Bleeding Risk and Computerized Decision Support for Stroke Prevention in Atrial Fibrillation: an AF-ALERT Substudy: Piazza: Outcomes of High-Bleeding Risk AF Patients. Piazza G, Hurwitz S, Carroll B, Goldhaber SZ. J Thromb Thrombolysis. 2020 Sep 30. doi: 10.1007/s11239-020-02296-0. Online ahead of print. PMID: 33000390
  1. Intermediate Versus Standard-Dose Prophylactic Anticoagulation and Statin Therapy Versus Placebo In Critically-Ill Patients with COVID-19: Rationale and Design of the INSPIRATION/INSPIRATION-S Studies. Bikdeli B, Talasaz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A, Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H, Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O, Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Thromb Res. 2020 Dec;196:382-394. doi: 10.1016/j.thromres.2020.09.027. Epub 2020 Sep 24. PMID: 32992075
  1. Correlation between Post-Procedure Residual Thrombus and Clinical Outcome in Deep Vein Thrombosis Patients Receiving Pharmacomechanical Thrombolysis in a Multicenter Randomized Trial. Razavi MK, Salter A, Goldhaber SZ, Lancia S, Kahn SR, Weinberg I, Kearon C, Azene EM, Patel NH, Vedantham S. J Vasc Interv Radiol. 2020 Oct;31(10):1517-1528.e2. doi: 10.1016/j.jvir.2020.07.010. Epub 2020 Sep 15. PMID: 32948386
  1. Mortality in Patients with Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, Goldhaber SZ, Goto S, Haas S, Mantovani LG, Kayani G, Grierson Turpie AG, Antoon Verheugt FW, Kakkar AK; GARFIELD-AF Investigators. J Am Coll Cardiol. 2020 Sep 22;76(12):1425-1436. doi: 10.1016/j.jacc.2020.07.045. PMID: 32943160
  1. Profile of Patients Diagnosed with Acute Venous Thromboembolism in Routine Practice According to Age and Renal Function: RE-COVERY DVT/PE Study. Ageno W, Casella IB, Chee KH, Schellong S, Schulman S, Singer DE, Desch M, Tang W, Voccia I, Zint K, Goldhaber SZ. J Thromb Thrombolysis. 2020 Aug 26. doi: 10.1007/s11239-020-02239-9. Online ahead of print. PMID: 32851572
  1. ECMO and Surgical Embolectomy: Two Potent Tools to Manage High-Risk Pulmonary Embolism. Goldhaber SZ. J Am Coll Cardiol. 2020 Aug 25;76(8):912-915. doi: 10.1016/j.jacc.2020.07.016. PMID: 32819464
  1. One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter- Based Fibrinolysis for Pulmonary Embolism. Piazza G, Sterling KM, Tapson VF, Ouriel K, Sharp ASP, Liu PY, Goldhaber SZ. Circ Cardiovasc Interv. 2020 Aug;13(8):e009012. doi: 10.1161/CIRCINTERVENTIONS.120.009012. Epub 2020 Aug 6. PMID: 32757658
  1. Cancer-associated Thrombosis in Everyday Practice: Perspectives from  GARFIELD-VTE. Weitz JI, Haas S, Ageno W, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Nielsen JD, Kayani G, Farjat AE, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK; GARFIELD-VTE investigators J Thromb Thrombolysis. 2020 Aug;50(2):267-277. doi: 10.1007/s11239-020-02180-x. PMID: 32583306
  1. New Artificial Intelligence Prediction Model Using Serial Prothrombin Time International Normalized Ratio Measurements in Atrial Fibrillation Patients on Vitamin K Antagonists: GARFIELD-AF. Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):301-309. doi: 10.1093/ehjcvp/pvz076. PMID: 31821482

John Fanikos, RPh – NATF Treasurer
  1. Atrial fibrillation patients on warfarin and their transition to direct oral anticoagulants. Collins P, Lewin A, Irving NV, Sylvester K, Fanikos J, Goldhaber SZ, Connors JM. Crit Pathw Cardiol. 2020 Dec 16;Publish Ahead of Print. doi: 10.1097/HPC.0000000000000251. Online ahead of print. PMID: 33337730
  1. Development of an Institutional Periprocedural Management Guideline for Oral Anticoagulants. Lewin AR, Collins PE, Sylvester KW, Rimsans J, Fanikos J, Goldhaber SZ, Connors JM.Crit Pathw Cardiol. 2020 Dec;19(4):178-186. doi: 10.1097/HPC.0000000000000221.PMID: 33186279
  1. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB, Morrison RB, Leiva O, Fanikos J, Nauffal V, Almarzooq Z, Goldhaber SZ.J Am Coll Cardiol. 2020 Nov 3;76(18):2060-2072. doi: 10.1016/j.jacc.2020.08.070.PMID: 33121712
  1. Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience. Sylvester KW, Wagner C, Lewin A, Fanikos J, Goldhaber SZ, Connors JM.J Thromb Thrombolysis. 2020 Oct 21. doi: 10.1007/s11239-020-02293-3. Online ahead of print.PMID: 33085044 

Jawed Fareed, PhD. – NATF Co-Chair of Research & Science
  1. Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. Siddiqui F, Antic D, Tafur A, Bontekoe E, Hoppensteadt D, Gerotziafas G, Elalamy I, Fareed J.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620983466. doi: 10.1177/1076029620983466. PMID: 33372544
  1. Prospective Assessment of Biomarkers of Hypercoagulability for the Identification of Patients With Severe Coronary Artery Disease. The ROADMAP-CAD Study. Gerotziafas GT, Zografos T, Pantos I, Lefkou E, Carlo A, Fareed J, Van Dreden P, Katritsis D.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620964590. doi: 10.1177/1076029620964590. PMID: 33284037 
  1. Studies on Tissue Factor Pathway Inhibitor Antigen Release by Bovine, Ovine and Porcine Heparins Following Intravenous Administration to Non-Human Primates. Kouta A, Hoppensteadt D, Bontekoe E, Jeske W, Duff R, Cera L, Fareed J.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620951851. doi: 10.1177/1076029620951851. PMID: 33034200
  1. Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components. Siddiqui F, Hoppensteadt D, Bontekoe E, Farooqui A, Jeske W, Fareed J.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620954913. doi: 10.1177/1076029620954913. PMID: 33030036
  1. Comparative Studies on the Anticoagulant Profile of Branded Enoxaparin and a New Biosimilar Version. Qneibi D, Ramacciotti E, Macedo AS, Caffaro RA, Agati LB, Siddiqui F, Kouta A, Hoppensteadt D, Fareed J, Carter CA.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620960820. doi: 10.1177/1076029620960820. PMID: 32996340 
  1. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, Antic D, Auad L, Banfic L, Bartolomew JR, Benczur B, Bernardo MB, Boccardo F, Cifkova R, Cosmi B, De Marchi S, Dimakakos E, Dimopoulos MA, Dimitrov G, Durand-Zaleski I, Edmonds M, El Nazar EA, Erer D, Esponda OL, Gresele P, Gschwandtner M, Gu Y, Heinzmann M, Hamburg NM, Hamadé A, Jatoi NA, Karahan O, Karetova D, Karplus T, Klein-Weigel P, Kolossvary E, Kozak M, Lefkou E, Lessiani G, Liew A, Marcoccia A, Marshang P, Marakomichelakis G, Matuska J, Moraglia L, Pillon S, Poredos P, Prior M, Salvador DRK, Schlager O, Schernthaner G, Sieron A, Spaak J, Spyropoulos A, Sprynger M, Suput D, Stanek A, Stvrtinova V, Szuba A, Tafur A, Vandreden P, Vardas PE, Vasic D, Vikkula M, Wennberg P, Zhai Z; Scientific Reviewer Committee.Thromb Haemost. 2020 Dec;120(12):1597-1628. doi: 10.1055/s-0040-1715798. Epub 2020 Sep 13. PMID: 32920811
  1. Response to Maccio et al, “Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?”. Richardson E, Carlo-Stella C, Jara R, Vlodavsky I, Iacobelli M, Fareed J, Mo C, O’Gorman P, Yanik G, Palomo M, Diaz-Ricart M, Moraleda JM; DEFACOVID Study Group.J Thromb Haemost. 2020 Nov;18(11):3111-3113. doi: 10.1111/jth.15088. PMID: 32860297
  1. Difficulties of Managing Submassive and Massive Pulmonary Embolism in the Era of COVID-19. Marginean A, Masic D, Brailovsky Y, Fareed J, Darki A.JACC Case Rep. 2020 Jul 15;2(9):1383-1387. doi: 10.1016/j.jaccas.2020.05.017. Epub 2020 May 19. PMID: 32835283
  1. Effect of a Recombinant Human Soluble Thrombomodulin on Baseline Coagulation Biomarker Levels and Mortality Outcome in Patients With Sepsis-Associated Coagulopathy. Levi M, Vincent JL, Tanaka K, Radford AH, Kayanoki T, Fineberg DA, Hoppensteadt D, Fareed J.Crit Care Med. 2020 Aug;48(8):1140-1147. doi: 10.1097/CCM.0000000000004426. PMID: 32697484
  1. Viral Coagulopathy in Patients With COVID-19: Treatment and Care. Kipshidze N, Dangas G, White CJ, Kipshidze N, Siddiqui F, Lattimer CR, Carter CA, Fareed J.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936776. doi: 10.1177/1076029620936776. PMID: 32687449 
  1. Impact of Pulmonary Embolism Response Team on Anticoagulation Prescribing Patterns in Patients With Acute Pulmonary Embolism. Kuhrau S, Masic D, Mancl E, Brailovsky Y, Porcaro K, Morris S, Haines J, Charo K, Fareed J, Darki A.J Pharm Pract. 2020 Jul 15:897190020940125. doi: 10.1177/0897190020940125. Online ahead of print. PMID: 32666864
  1. Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium? Guler N, Siddiqui F, Fareed J.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620935526. doi: 10.1177/1076029620935526. PMID: 32659106
  1. Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. Ramacciotti E, Macedo AS, Biagioni RB, Caffaro RA, Lopes RD, Guerra JC, Orsi FA, Marques MA, Tafur AJ, Caprini JA, Nicolaides A, Carter CA, Filho CC, Fareed J.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620936350. doi: 10.1177/1076029620936350. PMID: 32649232
  1. Structural characterization of a clinically described heparin-like substance in plasma causing bleeding.Yu Y, Bruzdoski K, Kostousov V, Hensch L, Hui SK, Siddiqui F, Farooqui A, Kouta A, Zhang F, Fareed J, Teruya J, Linhardt RJ.Carbohydr Polym. 2020 Sep 15;244:116443. doi: 10.1016/j.carbpol.2020.116443. Epub 2020 May 19.PMID: 32536393
  1. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group.Thromb Haemost. 2020 Jul;120(7):1004-1024. doi: 10.1055/s-0040-1713152. Epub 2020 May 30.PMID: 32473596

Gregory Piazza, MD, MS – NATF Chair of Healthcare Provider Engagement and Education
  1. Association of ABO blood group type with cardiovascular events in COVID-19. Nauffal V, Achanta A, Goldhaber SZ, Piazza G. J Thromb Thrombolysis. 2021 Jan 15. doi: 10.1007/s11239-020-02364-5. Online ahead of print. PMID: 33452583
  1. First-in-Human Study to Assess the Safety and Feasibility of the Bashir Endovascular Catheter for the Treatment of Acute Intermediate-Risk Pulmonary Embolism. Sista AK, Bhatheja R, Rali P, Natarajan K, Green P, Piazza G, Comerota AJ, Parikh SA, Lakhter V, Bashir R, Rosenfield K. Circ Cardiovasc Interv. 2021 Jan;14(1):e009611. doi: 10.1161/CIRCINTERVENTIONS.120.009611. Epub 2020 Dec 24. PMID: 33356383
  1. Update on Guidelines for the Management of Cancer-Associated Thrombosis. Streiff MB, Abutalib SA, Farge D, Murphy M, Connors JM, Piazza G. Oncologist. 2021 Jan;26(1):e24-e40. doi: 10.1002/onco.13596. Epub 2020 Dec 4. PMID: 33275332
  1. Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19. Piazza G, Morrow DA. JAMA. 2020 Dec 22;324(24):2548-2549. doi: 10.1001/jama.2020.23422. PMID: 33226423
  1. Identification and Outcomes of Hospitalized Medically Ill Patients Who Are Candidates for Extended Duration Thromboprophylaxis. Coleman CI, Piazza G, Ashton V, Bunz TJ, Spyropoulos AC. TH Open. 2020 Oct 31;4(4):e344-e350. doi: 10.1055/s-0040-1718911. eCollection 2020 Oct. PMID: 33145475
  1. Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review. Chopard R, Albertsen IE, Piazza G. JAMA. 2020 Nov 3;324(17):1765-1776. doi: 10.1001/jama.2020.17272. PMID: 33141212
  1. Advanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar. Piazza G. J Am Coll Cardiol. 2020 Nov 3;76(18):2117-2127. doi: 10.1016/j.jacc.2020.05.028. PMID: 33121720
  1. Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19. Piazza G, Campia U, Hurwitz S, Snyder JE, Rizzo SM, Pfeferman MB, Morrison RB, Leiva O, Fanikos J, Nauffal V, Almarzooq Z, Goldhaber SZ. J Am Coll Cardiol. 2020 Nov 3;76(18):2060-2072. doi: 10.1016/j.jacc.2020.08.070. PMID: 33121712
  1. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, Francese DP, Gibson CM, Piazza G, Goldhaber SZ, Eikelboom JW, Krumholz HM, Stone GW. Semin Thromb Hemost. 2020 Nov;46(8):908-918. doi: 10.1055/s-0040-1716874. Epub 2020 Oct 21. PMID: 33086402
  1. The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. Frydman GH, Streiff MB, Connors JM, Piazza G. TH Open. 2020 Oct 7;4(4):e288-e299. doi: 10.1055/s-0040-1718415. eCollection 2020 Oct. PMID: 33043235
  1. Patients with perceived high-bleeding risk and computerized decision support for stroke prevention in atrial fibrillation: an AF-ALERT substudy : Piazza: outcomes of high-bleeding risk AF patients. Piazza G, Hurwitz S, Carroll B, Goldhaber SZ. J Thromb Thrombolysis. 2020 Sep 30. doi: 10.1007/s11239-020-02296-0. Online ahead of print. PMID: 33000390
  1. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies. Bikdeli B, Talasaz AH, Rashidi F, Sharif-Kashani B, Farrokhpour M, Bakhshandeh H, Sezavar H, Dabbagh A, Beigmohammadi MT, Payandemehr P, Yadollahzadeh M, Riahi T, Khalili H, Jamalkhani S, Rezaeifar P, Abedini A, Lookzadeh S, Shahmirzaei S, Tahamtan O, Matin S, Amin A, Parhizgar SE, Jimenez D, Gupta A, Madhavan MV, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Mohebbi B, Piazza G, Kirtane AJ, Lip GYH, Krumholz HM, Goldhaber SZ, Sadeghipour P. Thromb Res. 2020 Dec;196:382-394. doi: 10.1016/j.thromres.2020.09.027. Epub 2020 Sep 24. PMID: 32992075
  1. Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. Bhatia K, Uberoi G, Bajaj NS, Jain V, Arora S, Tafur A, Bangalore S, Olin JW, Piazza G, Goldhaber SZ, Vaduganathan M, Qamar A. Am J Cardiol. 2020 Oct 15;133:175-178. doi: 10.1016/j.amjcard.2020.07.027. Epub 2020 Jul 25. PMID: 32807386
  1. One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism. Piazza G, Sterling KM, Tapson VF, Ouriel K, Sharp ASP, Liu PY, Goldhaber SZ. Circ Cardiovasc Interv. 2020 Aug;13(8):e009012. Doi: 10.1161/CIRCINTERVENTIONS.120.009012. Epub 2020 Aug 6. PMID: 32757658
  1. A fortune teller’s dream or clinician’s nightmare: Right ventricular assessment for risk prediction in pulmonary embolism. Piazza G. Thromb Res. 2020 Nov;195:169-170. doi: 10.1016/j.thromres.2020.07.032. Epub 2020 Jul 16. PMID: 32711232

Christian Ruff, MD, MPH – NATF Co-Chair Medical Advisory Board
  1. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Nelson SE, Giugliano RP, Antman EM, Park JG, Norden AD, Rost NS, Silverman S, Singhal AB, Lanz HJ, Braunwald E, Ruff CT; ENGAGE AF-TIMI 48 Steering Committee and Investigators.J Clin Neurosci. 2021 Jan 11:S0967-5868(20)31595-2. doi: 10.1016/j.jocn.2020.10.036. Online ahead of print. PMID: 33446422
  1. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients with Cardiometabolic Disease. Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT.Circ Genom Precis Med. 2021 Jan 12. doi: 10.1161/CIRCGEN.120.003006. Online ahead of print. PMID: 33434447
  1. Biomarkers for Risk Assessment in Atrial Fibrillation. Berg DD, Ruff CT, Morrow DA.Clin Chem. 2021 Jan 8;67(1):87-95. doi: 10.1093/clinchem/hvaa298. PMID: 33313695
  1. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. Carnicelli AP, Hong H, Giugliano RP, Connolly SJ, Eikelboom J, Patel MR, Wallentin L, Morrow DA, Wojdyla D, Hua K, Hohnloser SH, Oldgren J, Ruff CT, Piccini JP, Lopes RD, Alexander JH, Granger CB; COMBINE AF Investigators.Am Heart J. 2020 Dec 6;233:48-58. doi: 10.1016/j.ahj.2020.12.002. Online ahead of print. PMID: 33296688
  1. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients with Cardiometabolic Disease. Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng LC, Bonaca MP, Giugliano RP, Scirica BM, O’Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Steg PG, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT.Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.051927. Online ahead of print. PMID: 33185476
  1. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Vilain K, Li H, Kwong WJ, Antman EM, Ruff CT, Braunwald E, Cohen DJ, Giugliano RP, Magnuson EA; ENGAGE AF-TIMI 48 Trial Investigators.Circ Cardiovasc Qual Outcomes. 2020 Nov;13(11):e006511. doi: 10.1161/CIRCOUTCOMES.120.006511. Epub 2020 Nov 5. PMID: 33148013
  1. Response by Marston et al to Letter Regarding Article, “The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism”. Marston NA, Ruff CT, Sabatine MS.Circulation. 2020 Oct 27;142(17):e264. doi: 10.1161/CIRCULATIONAHA.120.050174. Epub 2020 Oct 26. PMID: 33104403
  1. Patients with diabetes mellitus and atrial fibrillation treated with NOACs: Meta-analysis of 8 outcomes in 58, 634 patients across 4 randomized controlled trials. Plitt A, Zelniker TA, Park JG, McGuire DK, Ruff CT, Antman EM, Braunwald E, Giugliano RP.Eur Heart J Cardiovasc Pharmacother. 2020 Oct 16:pvaa120. doi: 10.1093/ehjcvp/pvaa120. Online ahead of print. PMID: 33063112
  1. Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial. Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP.Thromb Haemost. 2020 Sep 13. doi: 10.1055/s-0040-1716540. Online ahead of print. PMID: 32920808

Jeanine Walenga, PhD. – NATF Co-Chair of Research & Science
  1. Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices. Walenga JM, Torres TA, Jeske WP, Schwartz J, Escalante V, Newman JD, Bakhos M.Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620959724. doi: 10.1177/1076029620959724. PMID: 32970454